SCHEMBL19968882

SCHEMBL19968882

CCCc1ccccc1-c1nc(NS(=O)(=O)c2cccc(N3CCC(C)CC3)n2)ccc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 5/20 0.37
SCN8A Q9UQD0 5/20 0.37
SCN9A Q15858 1/20 0.35
HSD11B1 P28845 1/20 0.35
C5AR1 P21730 1/20 0.34
EPHX2 P34913 3/20 0.33
CYP2C9 P11712 2/20 0.33
TRPV1 Q8NER1 4/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CTSS P25774 1/20 0.33
OGA O60502 1/20 0.33
CACNA1C Q13936 1/20 0.32
SCN5A Q14524 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968877 0.88 SCN1A (0.39) SCN1ASCN8ASCN9AHSD11B1C5AR1
SCHEMBL19968878 0.86 SCN1A (0.38) SCN1ASCN8ASCN9AHSD11B1MAPT
SCHEMBL29464538 0.86 RORC (0.33) SCN1ASCN8ASCN9AHSD11B1KDM4E
SCHEMBL19951366 0.86 RORC (0.33) SCN1ASCN8ASCN9AHSD11B1KDM4E
SCHEMBL23770778 0.85 SCN9A (0.37) SCN1ASCN8ASCN9ACACNA1CSCN5A
SCHEMBL19968873 0.85 SCN9A (0.36) SCN1ASCN8ASCN9AHSD11B1KDM4E
SCHEMBL19968816 0.85 SCN9A (0.36) SCN1ASCN8ASCN9AHSD11B1KDM4E
SCHEMBL22323499 0.84 S1PR1 (0.38) SCN1ASCN8AHSD11B1EPHX2CYP2C9
SCHEMBL19968901 0.83 SCN1A (0.35) SCN1ASCN8ASCN9ATRPV1KDM4E
SCHEMBL19968879 0.83 SCN1A (0.37) SCN1ASCN8ASCN9AHSD11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 SCN1A 32/4885SCN8A 450/4885SCN9A 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.